OTCMKTS:ARPO - Aerpio Pharmaceuticals Stock Price, Forecast & News

$0.61

0.00 (0.00 %)

(As of 01/19/2020 02:03 PM ET)

Add

Compare

Today's Range

$0.61

Now: $0.61▼

$0.64

50-Day Range

$0.54

MA: $0.59▼

$0.66

52-Week Range

$0.45

Now: $0.61▼

$4.25

Volume120,469 shs

Average Volume480,433 shs

Market Capitalization$24.96 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Aerpio Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes proprietary therapeutics for treating ocular diseases. The company's lead product candidate is AKB-9778, a small molecule activator of the tie-2 pathway, which completed Phase 2a clinical trials for the treatment of diabetic macular edema. It also develops ARP-1536, a humanized monoclonal antibody that is in late stage preclinical development for the treatment of wet age-related macular degeneration; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a Phase 1a clinical trial for the treatment of inflammatory bowel disease. Read More…

Industry, Sector and Symbol

Stock Exchange OTCMKTS

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolOTCMKTS:ARPO

Previous Symbol

CUSIPN/A

CIKN/A

Webhttp://www.aerpio.com/

Phone513-985-1920

Debt

Debt-to-Equity RatioN/A

Current RatioN/A

Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book ValueN/A

Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

EmployeesN/A

Outstanding Shares40,588,000

Market Cap$24.96 million

Next Earnings DateN/A

OptionableNot Optionable

Receive ARPO News and Ratings via Email

Sign-up to receive the latest news and ratings for ARPO and its competitors with MarketBeat's FREE daily newsletter.

Aerpio Pharmaceuticals (OTCMKTS:ARPO) Frequently Asked Questions

What is Aerpio Pharmaceuticals' stock symbol?

Aerpio Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ARPO."

How were Aerpio Pharmaceuticals' earnings last quarter?

Aerpio Pharmaceuticals Inc (OTCMKTS:ARPO) announced its quarterly earnings data on Thursday, November, 7th. The company reported ($0.11) EPS for the quarter, beating the Zacks' consensus estimate of ($0.13) by $0.02. View Aerpio Pharmaceuticals' Earnings History.

What price target have analysts set for ARPO?

4 analysts have issued 1-year price targets for Aerpio Pharmaceuticals' stock. Their forecasts range from $1.00 to $8.00. On average, they anticipate Aerpio Pharmaceuticals' share price to reach $4.50 in the next year. This suggests a possible upside of 631.8% from the stock's current price. View Analyst Price Targets for Aerpio Pharmaceuticals.

What is the consensus analysts' recommendation for Aerpio Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aerpio Pharmaceuticals in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Aerpio Pharmaceuticals.

What are Wall Street analysts saying about Aerpio Pharmaceuticals stock?

Here are some recent quotes from research analysts about Aerpio Pharmaceuticals stock:

1. According to Zacks Investment Research, "Aerpio Pharmaceuticals Inc. is a biopharmaceutical company. It focuses on the development of novel therapeutics for vascular disorders with a concentration on diseases of the eye. The Company' product candidates include AKB?9778, ARP1536 and AKB-4924 which are in clinical stage. Aerpio Pharmaceuticals Inc. is based in Cincinnati, United States. " (11/26/2019)
2. HC Wainwright analysts commented, "Our price target is derived from an estimated market value of the firm at $43M, which includes a discounted cash flow- based asset value for AKB-9778 in glaucoma and AKB-4924 (GB004) in inflammatory bowel disease (IBS), using a 15% discount rate and 2% terminal growth rate, and probabilities of success at 20% and 10%,." (8/9/2019)

Has Aerpio Pharmaceuticals been receiving favorable news coverage?

News stories about ARPO stock have trended positive recently, according to InfoTrie Sentiment. The research firm ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Aerpio Pharmaceuticals earned a media sentiment score of 2.7 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Aerpio Pharmaceuticals.

Who are some of Aerpio Pharmaceuticals' key competitors?

Some companies that are related to Aerpio Pharmaceuticals include Immunic (IMUX), Proteostasis Therapeutics (PTI), TFF Pharmaceuticals (TFFP), Inflarx (IFRX), Trevi Therapeutics (TRVI), Cyclerion Therapeutics (CYCN), Oramed Pharmaceuticals (ORMP), ASLAN PHARMACEU/ADR (ASLN), Enlivex Therapeutics (ENLV), Catalyst Biosciences (CBIO), Elite Pharmaceuticals (ELTP), ESSA Pharma (EPIX), Catabasis Pharmaceuticals (CATB), IMMUTEP LTD/S (IMMP) and Aclaris Therapeutics (ACRS).

What other stocks do shareholders of Aerpio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aerpio Pharmaceuticals investors own include Bausch Health Companies (BHC), Corbus Pharmaceuticals (CRBP), MannKind (MNKD), Actinium Pharmaceuticals (ATNM), AVEO Pharmaceuticals (AVEO), BIOLINERX LTD/S (BLRX), Eyegate Pharmaceuticals (EYEG), Progenics Pharmaceuticals (PGNX), Sorrento Therapeutics (SRNE) and Anavex Life Sciences (AVXL).

Who are Aerpio Pharmaceuticals' key executives?

Aerpio Pharmaceuticals' management team includes the folowing people:

Dr. Joseph H. Gardner, Founder, Pres & Director (Age 62)
Mr. Kevin G. Peters M.D., Ph.D., Chief Scientific Officer & Sr. VP (Age 61)
Dr. Stephen Pakola M.D., Chief Medical Officer (Age 49)
Dr. Stephen J. Hoffman, CEO & Director (Age 64)
Mr. Michael W. Rogers, Chief Financial Officer (Age 58)

How do I buy shares of Aerpio Pharmaceuticals?

Shares of ARPO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Aerpio Pharmaceuticals' stock price today?

One share of ARPO stock can currently be purchased for approximately $0.61.

How big of a company is Aerpio Pharmaceuticals?

Aerpio Pharmaceuticals has a market capitalization of $24.96 million. View Additional Information About Aerpio Pharmaceuticals.

What is Aerpio Pharmaceuticals' official website?

The official website for Aerpio Pharmaceuticals is http://www.aerpio.com/.

How can I contact Aerpio Pharmaceuticals?

Aerpio Pharmaceuticals' mailing address is 9987 CARVER ROAD, CINCINNATI OH, 45242. The company can be reached via phone at 513-985-1920 or via email at [email protected]

MarketBeat Community Rating for Aerpio Pharmaceuticals (OTCMKTS ARPO)

Community Ranking:		2.4 out of 5 ( )
Outperform Votes:		81 (Vote Outperform)
Underperform Votes:		88 (Vote Underperform)
Total Votes:		169

MarketBeat's community ratings are surveys of what our community members think about Aerpio Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARPO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARPO will underperform the S&P 500 over the long term. You may vote once every thirty days.

This page was last updated on 1/19/2020 by MarketBeat.com Staff

Your Ultimate Investing Toolkit

Just $1.00 for your first month.